Nivolumab
Metastasis From Malignant Tumor of Liver
Nanobiotixmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Metastasis From Malignant Tumor of Liver cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Nanobiotix | Phase 1 | CC |
Epirubicin Nanobiotix | Phase 1 | CC |
Pembrolizumab Nanobiotix | Phase 1 | CC |
HAFNIUM OXIDE Nanobiotix | Phase 1 | CC |
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →